ClinicalTrials.gg
CompletedNCT04893317CryoCure-VTUpdated Oct 13, 2026Results posted

Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)

An interventional study of Ablation in the ventricles with the Adagio Medical VT Cryoablation System in Monomorphic Ventricular Tachycardia, sponsored by Adagio Medical. Completed at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Enrollment
23rd of 39
64 · median 130
Started
2021
with 6 others
No phase
19 of 54
8 open now
Registered
38th of 54
by date
Lead sponsor
2 of 54
Adagio Medical

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2021, is one of 19 with no phase, and was the 38th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

A prospective, single-arm, multi-center, pre-market, clinical study designed to provide safety and performance data regarding the use of the Adagio Medical VT Cryoablation System in the treatment of ventricular tachycardia.

Read the detailed description

Study subjects will include patients who experience recurrent monomorphic VT and are scheduled for an endocardial VT ablation. Study subjects have or will have an Implantable Cardioverter Defibrillator (ICD) prior to hospital discharge following the cryoablation procedure.

A VT ablation procedure is performed by finding the abnormal ventricular heart tissue that is causing the VT and applying energy with an ablation catheter to the area. The goal is to apply energy to create a scar or destroy the tissue that causes the VT, such that VT is no longer present or inducible.

03

Conditions studied

  • Monomorphic Ventricular Tachycardia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IC 1 Male or female the ages of ≥ 18 years

IC 2 Eligible for a catheter ablation due to Ischemic and/or non-ischemic recurrent symptomatic sustained monomorphic Ventricular Tachycardia also defined as having a similar QRS configuration from beat to beat.

IC 3 Has or will be receiving an ICD prior to hospital discharge post procedure.

IC 4 to at least one AAD (Refractory is defined as an AAD not able to treat the arrhythmia satisfactorily or induces unwanted side effects).

IC 5 Subject has > 20%, confirmed by echo or comparable technique in the previous 3 months or during baseline evaluation

IC 6 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study

IC 7 Willingness and ability to give an

Exclusion criteria

Exclusion Criteria:

EC 1 Any known objective to ventricular tachycardia ablation, TEE, or anticoagulation, including but not limited to the identification of any cardiac thrombus or evidence of sepsis

EC 2 Any duration of continuous arrythmia that is not monomorphic ventricular tachycardia. Multiple monomorphic tachycardia is acceptable, but polymorphic VT is not.

EC 3 Any VT ablation within 4 weeks prior to enrollment

EC 4 More than one prior (>4 weeks) Ventricular Tachycardia ablation or prior surgical treatment for ventricular tachycardia

EC 5 Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause

EC 6 Structural heart disease as described below:

  1. Class IV heart failure
  2. Aortic aneurysm
  3. Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to the procedure
  4. Interatrial baffle, closure device, patch, or PFO occlusion device
  5. IVC filter
  6. Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure
  7. Severe Mitral or Aortic insufficiency or stenosis based on most recent TTE
  8. Cardiac myxoma
  9. Significant congenital anomaly
  10. Recent Myocardial Infarct (MI) or unstable angina, within 60 days prior to the ablation procedure
  11. Mechanical aortic or mitral valve

EC 7 Any previous history of cryoglobulinemia

EC 8 History of blood clotting or bleeding disease

EC 9 Any prior history of documented cerebral vascular accident (CVA), or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.

EC 10 Breastfeeding, pregnant, or anticipated pregnancy during study follow-up

EC 11 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study

EC 12 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a less than 12 months)

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Ablation in the ventricle with the Adagio VT cryoablation system

    all study subjects will receive an ablation procedure using the Adagio Medical VT Cryoablation System

    Device: Ablation in the ventricles with the Adagio Medical VT Cryoablation System

Interventions

  • DeviceAblation in the ventricles with the Adagio Medical VT Cryoablation System

    The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)

    An analysis of the proportion of subjects who are free from definite or probable device/procedure related Major Adverse Events (MAEs) that occur during or within 30 days following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion * Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation * Access site complications requiring medical or surgical intervention * Pericarditis * Heart block requiring a permanent pacemaker * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent DSMB to be probably or definitely related to the Adagio System.

    Time frame: during or within 30 days following the cryoablation procedure

  2. 6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)

    The primary clinical performance endpoint is an analysis of the proportion of patients receiving a single cryoablation procedure with freedom from ventricular tachycardia lasting longer than 30 seconds or appropriate ICD intervention until the end of the 6 month follow up period.

    Time frame: 6 month post cryoablation procedure

  3. Proportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure

    The primary procedural performance endpoint is an analysis of the proportion of subjects with non-inducible clinical monomorphic VT at the conclusion of the initial cryoablation procedure.

    Time frame: at the end of the cryoablation procedure

07

Results

Posted Oct 13, 2026

Participant flow

64 subjects were enrolled.

Participant flow — Overall Study
MilestoneAblation in the Ventricle With the Adagio VT Cryoablation System
Started64
Completed64
Not completed0

Outcome measures

PrimaryProportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)

An analysis of the proportion of subjects who are free from definite or probable device/procedure related Major Adverse Events (MAEs) that occur during or within 30 days following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion * Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation * Access site complications requiring medical or surgical intervention * Pericarditis * Heart block requiring a permanent pacemaker * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent DSMB to be probably or definitely related to the Adagio System.

Time frame:
during or within 30 days following the cryoablation procedure
Reported as:
Count of participants · Participants
Proportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)
ParticipantsAblation in the Ventricle With the Adagio VT Cryoablation System
Proportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)0
Primary6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)

The primary clinical performance endpoint is an analysis of the proportion of patients receiving a single cryoablation procedure with freedom from ventricular tachycardia lasting longer than 30 seconds or appropriate ICD intervention until the end of the 6 month follow up period.

Time frame:
6 month post cryoablation procedure
Reported as:
Number · percentage of participants
6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)
percentage of participantsAblation in the Ventricle With the Adagio VT Cryoablation System
6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)60.3
PrimaryProportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure

The primary procedural performance endpoint is an analysis of the proportion of subjects with non-inducible clinical monomorphic VT at the conclusion of the initial cryoablation procedure.

Time frame:
at the end of the cryoablation procedure
Reported as:
Number · percentage of participants
Proportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure
percentage of participantsAblation in the Ventricle With the Adagio VT Cryoablation System
Proportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure94.4

Adverse events

Collected over 12-month. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ablation in the Ventricle With the Adagio VT Cryoablation System1/64 (1.6%)4/64 (6.3%)0/64 (0%)
Most frequent serious events
Most frequent serious events
EventAblation in the Ventricle With the Adagio VT Cryoablation System
Pericardial effusionCardiac disorders2/64
Asymptomatic ventricular pseudo-aneurysmCardiac disorders1/64
Hemodynamic instabilityCardiac disorders1/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ablation in the Ventricle With the Adagio VT Cryoablation System
Mean67 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Ablation in the Ventricle With the Adagio VT Cryoablation System
Female3
Male61
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Ablation in the Ventricle With the Adagio VT Cryoablation System
Left Ventricular Ejection Fraction (LVEF)
Left Ventricular Ejection Fraction (LVEF)(%)Ablation in the Ventricle With the Adagio VT Cryoablation System
Mean35 ± 10
08

Study locations

7 sites
  • Onze Lieve Vrouwziekenhuis
    Aalst, 9300, Belgium
  • McGill University Health Centre
    Montreal, Canada
  • Montreal Hear Institute
    Montreal, Canada
  • Nemocnice na Homolce
    Prague, Czechia
  • CHU-Bordeaux, Pôle cardio-thoracique, Hôpital Haut-Lévêque
    Bordeaux, France
  • Herzzentrum Leipzig Universitätsklinik für Kardiologie
    Leipzig, Germany
  • St Antonius Ziekenhuis
    Nieuwegein, Netherlands
09

References and documents

Publications

  • Verma A, Essebag V, Neuzil P, Dyrda K, Balt J, Dinov B, Darma A, Arya A, Sacher F, Reddy VY, Boersma L, Grigorov I, De Potter T. Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2024 Mar 30;26(4):euae076. doi: 10.1093/europace/euae076. PubMed 38582974 ↗
  • De Potter T, Balt JC, Boersma L, Sacher F, Neuzil P, Reddy V, Grigorov I, Verma A. First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia. JACC Clin Electrophysiol. 2023 May;9(5):686-691. doi: 10.1016/j.jacep.2022.11.017. Epub 2023 Jan 18. PubMed 36752466 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2024, 37 months.

Results were first posted in Oct 2026, 2 years 3 months after primary completion.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 37 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
May 19, 2021
StartActual
May 26, 2021
Primary completionActual
Jun 30, 2024
CompletionActual
Sep 30, 2024
Results first posted
Oct 13, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Onze Lieve Vrouwziekenhuis · Aalst, Belgium
Show 1 removed
  • Onze Lieve Vrouwziekenhuis · Aalst, Belgium
Oct 13, 2026
Primary outcomes
3 added, 3 removed
What changed in the outcomes
  • AddedProportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)Time frame: during or within 30 days following the cryoablation procedure
  • Added6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)Time frame: 6 month post cryoablation procedure
  • AddedProportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation ProcedureTime frame: at the end of the cryoablation procedure
  • RemovedPrimary Endpoint for SafetyTime frame: during and 30 days post cryoablation procedure
  • RemovedPrimary Endpoint for Clinical PerformanceTime frame: 6 month post cryoablation procedure
  • RemovedPrimary Endpoint for Procedure PerformanceTime frame: at the end of the cryoablation procedure
Oct 13, 2026
Documents
Oct 13, 2026
Secondary outcomes
14 removed
What changed in the outcomes
  • RemovedSafety - freedom from procedure or device related SAETime frame: 12 months post cryoablation procedure
  • RemovedPerformance - non-inducible sustained monomorphic VTTime frame: at the end of the cryoablation procedure
  • RemovedPerformance - freedom from VT at 12-M off AADsTime frame: 12 months post cryoablation procedure
  • RemovedPerformance - freedom from VT at 12-M on previously failed AADsTime frame: 12 months post cryoablation procedure
  • RemovedPerformance - VT burdenTime frame: 6 and 12 months post cryoablation procedure
  • RemovedDescriptive Statistical Outcome - fluoroscopy timeTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - ablation timeTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - procedure timeTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - cryoablation lesionsTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - inducible VTsTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - ICD shocksTime frame: 12 months post cryoablation procedure
  • RemovedDescriptive Statistical Outcome - ablation strategiesTime frame: at the end of the cryoablation procedure
  • RemovedDescriptive Statistical Outcome - HospitalizationTime frame: 12 months post cryoablation procedure
  • RemovedDescriptive Statistical Outcome - AADs useTime frame: 12 months post cryoablation procedure
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Results posted
    Documents Study protocol ↗ posted
    1 site added, 1 site removed
    Show site
    • Onze Lieve Vrouwziekenhuis · Aalst, Belgium
    Show 1 removed
    • Onze Lieve Vrouwziekenhuis · Aalst, Belgium
    Primary outcomes 3 added, 3 removed
    What changed in the outcomes
    • AddedProportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)Time frame: during or within 30 days following the cryoablation procedure
    • Added6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)Time frame: 6 month post cryoablation procedure
    • AddedProportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation ProcedureTime frame: at the end of the cryoablation procedure
    • RemovedPrimary Endpoint for SafetyTime frame: during and 30 days post cryoablation procedure
    • RemovedPrimary Endpoint for Clinical PerformanceTime frame: 6 month post cryoablation procedure
    • RemovedPrimary Endpoint for Procedure PerformanceTime frame: at the end of the cryoablation procedure
    Secondary outcomes 14 removed
    What changed in the outcomes
    • RemovedSafety - freedom from procedure or device related SAETime frame: 12 months post cryoablation procedure
    • RemovedPerformance - non-inducible sustained monomorphic VTTime frame: at the end of the cryoablation procedure
    • RemovedPerformance - freedom from VT at 12-M off AADsTime frame: 12 months post cryoablation procedure
    • RemovedPerformance - freedom from VT at 12-M on previously failed AADsTime frame: 12 months post cryoablation procedure
    • RemovedPerformance - VT burdenTime frame: 6 and 12 months post cryoablation procedure
    • RemovedDescriptive Statistical Outcome - fluoroscopy timeTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - ablation timeTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - procedure timeTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - cryoablation lesionsTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - inducible VTsTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - ICD shocksTime frame: 12 months post cryoablation procedure
    • RemovedDescriptive Statistical Outcome - ablation strategiesTime frame: at the end of the cryoablation procedure
    • RemovedDescriptive Statistical Outcome - HospitalizationTime frame: 12 months post cryoablation procedure
    • RemovedDescriptive Statistical Outcome - AADs useTime frame: 12 months post cryoablation procedure
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04893317
Lead sponsor
Adagio Medical
Responsible party
Sponsor
First posted
May 19, 2021
Start date
May 26, 2021
Primary completion
Jun 30, 2024
Completion
Sep 30, 2024
Results posted
Oct 13, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion